drugset / Trial / NCT05799521

A Nasal Treatment for COVID-19

NCT05799521

Phase 2 Active not recruiting 24 enrolled Indiana University
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to test an investigational new inhaled medication called Optate.

Timeline

Start
2023-06-27
Primary completion
2027-03-30
Completion
2027-03-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycine Other / unclassified Inhaled

Indications